Search results for "Octreotate"

showing 3 items of 3 documents

Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal.

2020

Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (177Lu-DOTA0 Tyr 3 octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish pr…

Oncologymedicine.medical_specialtycatecholaminergic crisisMEDLINElcsh:Medicinecarcinoid syndrome030209 endocrinology & metabolismReviewNeuroendocrine tumors03 medical and health scienceschemistry.chemical_compound0302 clinical medicinesystematic reviewInternal medicinemedicinecarcinoid crisisProgression-free survivalDOTA-TATEpeptide receptor radionuclide therapyhormonal crisisOctreotatebusiness.industrySomatostatin receptorlcsh:RGeneral Medicinemedicine.diseaseSystematic reviewchemistry030220 oncology & carcinogenesisneuroendocrine tumorsbusiness177Lu-DOTA-TATECarcinoid syndromeJournal of clinical medicine
researchProduct

closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for B…

2008

Despite the improvements in cancer therapy during the past years, high-grade gliomas and many other types of cancer are still extremely resistant to current forms of therapy. Boron neutron capture therapy (BNCT) provides a promising way to destroy cancer cells without damaging healthy tissue. However, BNCT in practice is still limited due to the lack of boron-containing compounds that selectively deliver boron to cancer cells. Since many neuroendocrine tumors show an overexpression of the somatostatin receptor, it was our aim to synthesize compounds that contain a large number of boron atoms and still show high affinity toward this transmembrane receptor. The synthetic peptide Tyr (3)-octre…

inorganic chemicalsStereochemistryBiomedical EngineeringPharmaceutical ScienceBioengineeringPeptideBoron Neutron Capture TherapyCHO CellsConjugated systemBoranePeptides CyclicCell Linechemistry.chemical_compoundCricetulusCricetinaeNeoplasmsMoietyAnimalsHumansBinding siteBoranesPharmacologychemistry.chemical_classificationOctreotateBinding SitesSomatostatin receptorOrganic ChemistryCell MembranechemistryCancer cellBiotechnologyBioconjugate chemistry
researchProduct

Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy

2003

Abstract A novel Tyr 3 -octreotate conjugated closo -carborane as a potential compound for boron neutron capture therapy was obtained via Fmoc solid phase peptide synthesis. The boron cluster [C 2 B 10 H 11 ] was introduced through the reaction of 6,9-bis(acetonitrile)decaborane and 5-hexynoic acid yielding a new closo -carborane conjugated carboxylic acid which was coupled subsequently with solid phase conjugated Tyr 3 -octreotate. The final boron-containing peptide was purified by preparative reverse phase HPLC and structural identity was proved applying MALDI-TOF mass spectrometry.

inorganic chemicalschemistry.chemical_classificationOctreotateCarboxylic acidOrganic Chemistrychemistry.chemical_elementConjugated systemBiochemistryMedicinal chemistrychemistry.chemical_compoundchemistryDecaboraneDrug DiscoveryPeptide synthesisCarboraneAcetonitrileBoronNuclear chemistryTetrahedron Letters
researchProduct